Caribou Biosciences, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Caribou Biosciences, Inc. (CRBU) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$148.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-05
- Caribou Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$148.70M.
- Caribou Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$149.10M.
- Caribou Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$101.90M.
- Caribou Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$99.40M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$148.70M 10-K · filed 2026-03-05 |
| 2024-12-31 | -$149.10M 10-K · filed 2026-03-05 |
| 2023-12-31 | -$101.90M 10-K · filed 2025-03-10 |
| 2022-12-31 | -$99.40M 10-K · filed 2024-03-11 |
| 2021-12-31 | -$66.60M 10-K · filed 2023-03-09 |
| 2020-12-31 | -$36.10M 10-K · filed 2022-03-21 |
| 2019-12-31 | -$31.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |